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Aims: We aimed to conduct a meta-analysis of serious adverse events (macro- and 
micro-vascular events, falls and fractures, death) associated with hypoglycaemia in 
older patients. 
Methods: We searched MEDLINE and EMBASE spanning a ten-year period up to 
March 2015 (with automated PubMed updates to October 2015). We selected 
observational studies reporting on hypoglycaemia and associated serious adverse 
events, and conducted a meta-analysis.  We assessed study validity based on 
ascertainment of hypoglycaemia, adverse events and adjustment for confounders. 
Results: We included 17 studies involving 1.5 million participants.  Meta-analysis of 
eight studies demonstrated that hypoglycemic episodes were associated with 
macrovascular complications, odds ratio (OR) 1.83 (95% Confidence Interval [CI] 
1.64, 2.05), and microvascular complications in two studies OR 1.77 (95% CI 1.49, 
2.10).  Meta-analysis of four studies demonstrated an association between 
hypoglycaemia and falls or fractures, OR 1.89 (95% CI 1.54, 2.32) and 1.92 (95% CI 
1.56, 2.38) respectively. Hypoglycaemia was associated with increased likelihood of 
death in a meta-analysis of eight studies, OR 2.04 (95% Confidence Interval 1.68, 
2.47).   
Conclusion: Our meta-analysis raises major concerns about a range of serious 
adverse events associated with hypoglycaemia. Clinicians should prioritize 
individualized therapy and closer monitoring strategies to avoid hypoglycaemia in 
susceptible older patients. 
 
Keywords: Hypoglycaemia, Diabetes Mellitus, Falls, Fractures, Cardiovascular Disease 
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Introduction 
Diabetes is major chronic disease, affecting millions of people worldwide. In the UK, 
it is seen in 10-25% of older people and is often associated with other co-
morbidities, such as cardiovascular disease and cognitive impairment (Sinclair et al., 
2001).  Hamada et al found that 28% of over 80-year olds in the UK had co-morbid 
diabetes and cardiovascular disease and 5% had co-morbid diabetes and cognitive 
impairment/dementia (Hamada and Gulliford, 2015).  This vulnerable group of 
people is also at an increased risk of falls (Schwartz et al., 2008), which result in an 
estimated £1.1billion in hospital costs annually from hip fractures in the UK (Leal et 
al., 2015). 
 
Hypoglycaemia is a well-recognised side effect of diabetes treatment and concerns 
have been raised about potentially serious consequences of hypoglycaemia on the 
cardiovascular system and cognition in older people (Frier et al., 2011) (Mattishent 
and Loke, 2015). Bloomfield et al found evidence for an association between severe 
hypoglycaemia and all-cause mortality, neurological events, hospital and emergency 
department utilization and decreased quality of life, but there was insufficient data 
on cardiovascular disease, falls and traumatic injuries (Bloomfield et al., 2012).  More 
recent evidence has since emerged from an observational study reporting an 
association between hypoglycaemia and falls, whilst a meta-analysis of six studies 
revealed a significantly increased likelihood of cardiovascular disease associated with 
severe hypoglycaemia (Chiba et al., 2015) (Goto et al., 2013).  
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In light of these recent developments, we aimed to systematically review and 
analyze contemporary evidence on the relationship between hypoglycaemia and 
adverse events (vascular events, falls and fractures, death) in older patients treated 
with glucose lowering drugs.  We focused on vascular adverse events because 
patients with diabetes have an increased risk of micro- and macro- vascular disease 
(Bloomfield et al., 2012) and cardiovascular events remains the primary cause of 
death among insulin-treated people with diabetes (Khunti et al., 2015). We also 
aimed to evaluate falls and fractures because injuries are a leading cause of death in 
older people and can result in significant physical, psychological and social 
consequences (Thapa et al., 1996). 
 
Material and Methods 
 
Data sources and searches 
Our database search covered MEDLINE and EMBASE for 10 years up to March 2015 
(details of the search are provided in the supplementary eMethods), restricted to 
English language articles. The search was focused on the last 10 years, as we wanted 
more recent studies based on contemporary practice and populations. In addition, 
we received PubMed automated updates (most recent October 2015) regarding 
newly published articles on hypoglycaemia in older patients. We reviewed the 
reference lists of included studies for any potentially relevant studies.  
 
Study selection 
We specified inclusion criteria for cohort studies (prospective and retrospective), 
that examined the association between hypoglycaemia and serious adverse events. 
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We included studies that enrolled participants aged >55 years who had pre-diabetes 
or diabetes mellitus. The outcomes of interest were macro- and micro-vascular 
events, fall, fractures, and death. We excluded reviews and abstracts. 
 
Data extraction and quality assessment 
Study screening and data extraction was performed by the authors, by 
independently scanning all titles and abstracts for relevant articles, before obtaining 
full text versions for further checking. YKL and KM resolved uncertainties and 
discrepancies through discussion.   
 
Data collection was completed by using a standardized form, which included details 
of the study design, date of the study and country of origin, setting, selection 
criteria, participants’ characteristics and outcome measures.  Odds or hazard ratios 
were extracted as a measure of the association between hypoglycaemia and adverse 
events. 
 
In order to assess study validity, YKL and KM independently checked the methods 
used for recording hypoglycaemia and determining serious adverse events, as well as 
adjustment for potential confounding factors. 
 
Data synthesis and analysis 
A random effects meta-analysis of odds ratios using inverse variance method 
(Revman 5.3, Nordic Cochrane Centre, Kobenhavn) was performed.   Heterogeneity 
was assessed by using the chi-squared test, I2 statistic and visual inspection of the 
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forest plots. We aimed to construct a Funnel plot if we had more than 10 studies in 
the meta-analysis (without evidence of statistical heterogeneity).  We did not have a 
pre-registered protocol on web registry. 
 
Results 
We screened 1273 citations and included 17 studies with a total of 1498358 
participants in the meta-analysis (Bonds et al., 2010, Chiba et al., 2015, Duckworth et 
al., 2011, Hsu et al., 2013, Origin Trial Investigators et al., 2013, Johnston et al., 2012, 
Johnston et al., 2011, Kachroo et al., 2015, Khunti et al., 2015, Majumdar et al., 2013, 
McCoy et al., 2012, Rajpathak et al., 2015, Rathmann et al., 2013, Signorovitch et al., 
2013, Zhao et al., 2012, Zhao et al., 2015, Zoungas et al., 2010).  The flow chart of the 
study selection in shown in the supplementary eFigure. Characteristics of the 
included studies and participants are shown in the supplementary eTable. 
The included studies consisted of twelve retrospective, one prospective and four 
post-hoc analyses of randomized controlled trials (RCTs).  The studies had a total of   
participants (sample size from 211 to 860,845).  Geographical locations were diverse 
and included North America, Japan, Taiwan and Europe. All the included studies 
were conducted in older patients (mean age >60 years, or participants selected on 
basis of being 60 years of age or older). 
Thirteen studies focused on patients with Type 2 diabetes, whereas the remaining 
four had a mix of Type 1, Type 2 and impaired glucose tolerance/impaired fasting 
glucose.  Four of the studies looked only at oral agents.  The remaining studies 
included insulin users as well as patients on oral antidiabetic drugs (or a mix of 
insulin and tablets). 
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We report details of study validity (ascertainment of adverse outcomes, and 
confounding factors) in Table 1, and summarize the key features below. 
 
Measurement of hypoglycemic events 
Most of the studies relied on hospital or claims data records.  Two studies provided 
participants with diaries and glucose meters (Origin Trial Investigators et al., 2013) 
(Bonds et al., 2010) and two studies relied on questionnaires (Chiba et al., 2015) 
(McCoy et al., 2012). Two of the studies relied on routine trial monitoring 
(Duckworth et al., 2011) (Zoungas et al., 2010). 
Measurement of adverse events 
Four of the included studies used pre-specified outcomes from RCTs with 
independent adjudication by a blinded committee.  Twelve studies measured 
adverse events through database or medical records codes and one study relied on a 
professional interviewer with questionnaire (Chiba et al., 2015). 
 
Confounding factors 
All studies attempted to address confounding through the use of multiple logistic 
regression models, and in addition three studies used Propensity Scores (Hsu et al., 
2013) (Origin Trial Investigators et al., 2013, Zhao et al., 2012) . 
 
Meta-analysis 
Association between hypoglycaemia and vascular disease (Figure 1) 
We included eight studies in the meta-analysis for macrovascular 
complications(Duckworth et al., 2011, Hsu et al., 2013, Origin Trial Investigators et 
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al., 2013, Johnston et al., 2011, Khunti et al., 2015, Rathmann et al., 2013, Zhao et 
al., 2012, Zoungas et al., 2010) . The pooled odds ratio was 1.83 (95% Confidence 
Interval 1.64, 2.05).  There was moderate heterogeneity (chi-squared p= 0.07, 
I2=46%).  Hypoglycaemia was significantly associated with macrovascular 
complications. 
 
There are two studies in the meta-analysis which reported on the association 
between hypoglycaemia and microvascular complications (Zhao et al., 2012, Zoungas 
et al., 2010).  The pooled odds ratio was 1.77 (95% Confidence Interval 1.49, 2.10) 
with no evidence of heterogeneity (chi-squared p= 0.90, I2=0%). 
 
Association between hypoglycaemia and falls or fractures (Figure 2) 
There are four studies reporting on falls (Chiba et al., 2015) (Kachroo et al., 2015) 
(Signorovitch et al., 2013) (Zhao et al., 2015) with a pooled odds ratio of 1.89 (95% 
Confidence Interval 1.54, 2.32) and moderate heterogeneity (chi-squared p= 0.16, 
I2=43%). 
We included three studies for fractures (Johnston et al., 2012) (Kachroo et al., 2015) 
(Rajpathak et al., 2015) with a pooled odds ratio of 1.92 (95% Confidence Interval 
1.56, 2.38) and substantial heterogeneity (chi-squared p= 0.07, I2=63%). 
 
Association between hypoglycaemia and mortality (Figure 3) 
There are eight studies reporting on overall mortality with a pooled odds ratio of 
2.04 (95% Confidence Interval 1.68, 2.47) with substantial heterogeneity (chi-
squared p< 0.001, I2=82%)(Bonds et al., 2010, Hsu et al., 2013, Origin Trial 
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Investigators et al., 2013, Khunti et al., 2015, Majumdar et al., 2013, McCoy et al., 
2012, Zhao et al., 2012, Zoungas et al., 2010). Despite the heterogeneity, we note 
that direction of association was consistent across all the studies in the Forest plot. 
 
We explored the contribution of the specific studies to the heterogeneity, by 
removing single studies, one at a time, and we found that the only occasion where 
heterogeneity was markedly reduced (from 82% to 63%) was when Zhao’s study was 
excluded. (Zhao et al., 2012)  This is the only study that did not find a statistically 
significant association between hypoglycaemia and mortality (Hazard Ratio 1.29 with 
a 95% Confidence Interval 0.94, 1.77), which the authors attributed to small sample 
size (number of patients evaluated in the matched cohort was 1522). 
 
We identified two studies that reported on the association between hypoglycaemia 
and a death due to a cardiovascular cause (Origin Trial Investigators et al., 2013) 
(Zoungas et al., 2010). The pooled OR was 2.07 (95% Confidence Interval 1.34, 3.21) 
for this association. 
 
Sensitivity Analysis 
We aimed to clarify the temporal relationship between cardiovascular events and 
hypoglycaemia through a sensitivity analysis restricted to studies that excluded 
participants who had a history of recent macrovascular events. Pooled analysis of 
three studies showed that hypoglycaemia was significantly associated with new-
onset macrovascular events, OR 1.76 (1.42, 2.18).  
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Publication bias and selective outcome reporting 
We did not construct a funnel plot, because we did not have more than ten studies 
for any specific outcome. 
 
Discussion 
Our meta-analysis of 17 observational studies (involving a total of almost 1.5 million 
participants) raises major concerns about a range of serious adverse events 
associated with hypoglycaemia in older patients treated with glucose-lowering 
drugs.  We found consistent evidence of an 80% relative increase in the likelihood of 
vascular events (both macro- and microvascular complications, as well as 
cardiovascular death) with hypoglycemic episodes.  Our meta-analysis also addresses 
previous uncertainties by revealing a significant relationship between hypoglycaemia 
and risk of falls and fractures, as well as a doubling in the likelihood of death. The 
abundance and consistency of evidence regarding serious harm leads us to believe 
that treatment strategies aimed at minimizing hypoglycaemia should be prioritized 
in older patients who are already prone to suffer from cardiovascular events, falls, 
and fractures. 
 
There are a number of proposed biological mechanisms behind the adverse impact 
of hypoglycaemia on the cardiovascular system.  Hypoglycaemia can lead to 
activation of the sympatho-adrenal system resulting in end-organ stimulation and 
release of adrenaline.  This in turn provokes autonomic and hemodynamic changes 
resulting in an increased heart rate and peripheral systolic blood pressure, a fall in 
central blood pressure, reduced peripheral arterial resistance, increased myocardial 
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contractility, stroke volume and cardiac output (Frier et al., 2011) (Wright and Frier, 
2008).  The effect of all of these physiological changes is cardiac stress, which can 
have potentially serious consequences (eg myocardial ischaemia) in older people 
with diabetes and likely underlying coronary artery disease.  In addition, the first 
hypoglycemic episode can lead to further episodes that are asymptomatic and 
associated with cardiovascular and proarrhythmic changes (Zhao et al., 2012).  
Evidence has also shown that hypoglycaemia can result in abnormal electrical 
activity in the heart, strengthening the theory that hypoglycaemia can provoke 
sudden death (Frier et al., 2011).  Episodes of hypoglycaemia also result in impaired 
cardiac autonomic function which is associated with increased mortality among with 
patients at high cardiovascular risk, including those with diabetes (Zoungas et al., 
2010). 
 
Interestingly, Yun et al have recently published the findings of a prospective cohort 
study demonstrating that a history of cardiovascular disease was an independent risk 
factor for the development of severe hypoglycaemia (Yun et al., 2015). In order to 
assess the possibility of cardiovascular disease causing hypoglycaemia rather than 
the other way round, we conducted a sensitivity analysis based on studies that 
excluded patients with recent cardiovascular events. Our findings indicate that 
hypoglycaemia was associated with incident cardiovascular events, even in those 
patients with no cardiovascular history. Khunti et al. assessed the association 
between hypoglycaemia and cardiovascular events in subgroups of patients with, or 
without cardiovascular history, and found that the risk was similarly elevated in both 
subgroups, (Khunti et al., 2015) thus refuting Yun’s hypothesis.  
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Alternatively, hypoglycaemia may simply be a surrogate marker/indicator for greater 
disease burden or frailty in older patients, and there may actually be no direct 
mechanistic pathway linking hypoglycaemia to cardiovascular events or death(Bonds 
et al., 2010, Origin Trial Investigators et al., 2013) . However, Goto’s review included 
a bias analysis which reported that comorbid severe illness alone would not be 
sufficient to explain the reported association between hypoglycaemia and 
cardiovascular disease. (Goto et al., 2013) Given the multi-factorial nature of adverse 
events in the elderly, it seems prudent to consider that hypoglycaemia may be one 
factor amongst a host of others that can contribute to serious harm, and that all 
efforts should be made to reduce this risk. It is also tempting to speculate whether 
hypoglycaemia episodes that trigger acute cardiovascular events may be the unifying 
factor in explaining the associated falls and increased mortality (particularly as our 
meta-analysis identified an increased likelihood of death from cardiovascular cause 
in patients with hypoglycaemia). 
 
Strengths 
Our systematic review and meta-analysis provides a comprehensive synthesis of the 
most up to date evidence covering a range of adverse events that are a major 
burden in older patients with diabetes. We have overcome the uncertainties 
regarding cardiovascular events and fall/fractures that were limitations within 
Bloomfield’s wide-ranging systematic review (Bloomfield et al., 2012). We have 
further built upon Goto’s cardiovascular-focused systematic review,(Goto et al., 
2013) by including additional studies to distinguish between macrovascular and 
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microvascular events, and conducting a specific analysis of cardiovascular deaths and 
overall mortality, rather than just composite cardiovascular events.  
 
Limitations 
We are aware of limitations in our meta-analyses, in particular the inability to prove 
causality due to the observational nature of the studies. However, we do not 
consider it ethical or feasible to conduct a randomized trial in older patients to 
expose them to hypoglycaemia.  We chose to restrict our search to articles published 
in the past 10 years in order to focus on contemporary management of diabetes 
mellitus rather than more historical approaches, and our synthesis was restricted to 
English-language articles only.   
 
There is some heterogeneity, especially regarding the association between 
hypoglycaemia and mortality. This may stem from differences amongst the included 
study designs, which included post-hoc analyses of randomized controlled trials, in 
contrast to observational studies involving healthcare databases. We also noted 
considerable variation in the severity of disease and use of hypoglycaemic agents in 
the patients, and this may account for heterogeneity in subsequent risk of adverse 
events.  Moreover, the included studies employed a very wide definition of adverse 
events, particularly when constructing a composite endpoint for vascular disease.  
This stems from the variation in the use of administrative codes for the definition of 
cardiovascular events, as well as hypoglycaemia.  
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Our systematic review and meta-analysis highlights the importance of avoiding 
hypoglycaemia. This is especially true in older patients with diabetes mellitus and 
other co-morbidities, as they are at risk of serious adverse events associated with 
hypoglycemic episodes.  Individualized treatment rather than achieving rigid targets 
should be a priority.  This approach has recently also been highlighted by Caverley et 
al and coincides with the Department of Veterans’ Affairs’ launch of a hypoglycaemia 
safety initiative to decrease overtreatment among veterans with diabetes mellitus 
(Caverly et al., 2015) (Office of Public and Intergovernmental Affairs, 2014). Older 
patients and their physicians should aim to strike a pragmatic individualized balance 
between tight blood sugar control against the avoidance of adverse drug reactions, 
in particular hypoglycaemia and its associated serious harm. 
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Table 1: Study outcomes, results and risk of bias 
Study ID Method of diagnosing each type of 
adverse event 
Method of diagnosing or 
determining that patients had 
hypoglycemia 
Statistical adjustments for confounding 
factors (if any) 
Results with 95% CI 
Bonds 2010 
(Bonds et al., 
2010) 
Pre-specified primary outcome: non-
fatal MI or non-fatal stroke and 
cardiovascular death 
 
Pre-specified secondary outcome: all 
cause mortality 
 
Blinded independent adjudication of 
outcomes 
Investigators asked patients (who 
were given home glucose monitors) 
about hypoglycemic events at each 
visit. 
-symptomatic severe hypoglycemic 
event requiring medical assistance 
(HMA); blood glucose <2.8mmol/L or 
symptoms resolved with treatment 
-symptomatic severe hypoglycemic 
event requiring any assistance (HA) 
Cox regression models (stepwise 
procedure) 
 
Confounders: baseline covariates, age, 
gender, ethnicity, education, BMI, 
alcohol, smoking, cardiovascular disease, 
diabetes duration, diabetic 
complications, cardiovascular risk 
factors, medication, trial treatment 
assignment 
Association between any 
hypoglycemic event and 
mortality  
intensive arm aHR 1.41 
(1.03, 1.93) 
 
standard care arm aHR 
2.30 (1.46, 3.65) 
 
 
Chiba 2015 
(Chiba et al., 
2015) 
Professional interviewer with 
questionnaire about frequency and type 
of falls (defined as unexpected event in 
which the person came to rest on the 
ground, floor, lower level.  Complicated 
with a head injury or fractures).   
Professional interviewer with 
validated questionnaire regarding 
hypoglycemic symptoms. 
Severe: coma, convulsion, inability of 
self-management and recovery from 
symptoms. 
Mild: hypoglycemic symptoms with 
recovery within 10 minutes by self-
administered sugar or glucose. 
Multiple regression analysis: age, sex, 
cognitive impairment (MMSE <26), TUG 
score, GDS-15 scores, Falls Risk Index, 
presence of hypoglycemia. 
Presence of 
hypoglycemia OR 3.62 
(1.24, 10.53), associated 
with presence of 
multiple falls, and any 
fall OR 2.05 (0.93-4.535). 
Prevalence of falls 
increased as the 
frequency of 
hypoglycemia increased. 
Duckworth 
2011 
(Duckworth et 
al., 2011) 
Cardiovascular event is pre-specified 
composite: MI, stroke, CV death, cardiac 
failure, vascular surgery, inoperable 
coronary artery disease, amputation for 
gangrene 
 
Blinded independent adjudication of 
outcomes 
Routine trial monitoring for adverse 
events 
Multivariate regression analysis 
 
Confounders: prior cardiovascular event, 
age, baseline insulin, ethnicity, smoking 
status, HbA1c, lipids, creatinine, 
diabetes treatment and duration 
HR for composite 
cardiovascular event 
1.88 (1.029, 3.432) 
Hsu 2013 (Hsu Cancer, stroke, coronary heart disease Hospital claims dataset for severe Propensity score, Cox proportional HR 2.09 (1.63, 2.67) for 
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et al., 2013) and cardiovascular disease identified 
from hospital claims dataset, ICD-9-CM 
codes 
 
Death status ascertained according to 
discharge reasons with death or critically 
ill at discharge, or if insurance cover 
stopped due to death. 
hypoglycemia 
Outpatient claims dataset for mild 
hypoglycemia 
ICD-9-CM codes 
hazard model, Kaplan-Meier 
 
Variables in propensity score matching: 
age, sex, diabetes duration, 
hypertension, heart disease, renal and 
liver disease, cancer, mental disease, 
socio-economic status, treatment 
adherence. 
cardiovascular diseases, 
HR 2.51 (2.00, 3.16) for 
all-cause hospitalisation, 
HR 2.48 (1.41, 4.38) for 
total mortality 
Johnston 2011 
(Johnston et al., 
2011) 
Acute cardiovascular events: coronary 
artery bypass graft, revascularisation, 
percutaneous coronary intervention –
≥one inpatient or outpatient claim ICD-
9-CM code 
Acute MI, incident unstable angina – ≥1 
inpatient claim with an ICD-9-CM code 
≥1 outpatient claim with ICD-9-CM 
diagnosis code for hypoglycemia 
(hypoglycemic events were allowed 
to occur at any time during the 
evaluation period, including after 
acute cardiovascular events) 
Multiple logistic regression and 
backwards stepwise selection 
Adjusted for age, sex, geography, 
insurance type, comorbidity scores, 
cardiovascular risk and prior events, 
diabetes complications, total baseline 
medical expenditures. 
OR 1.79 (1.69, 1.89) for 
acute cardiovascular 
events 
 
Patients >age 65 years 
OR1.78 (1.65, 1.92) 
Johnston 2012 
(Johnston et al., 
2012) 
Emergency department claim with ICD-
9-CM diagnosis code, for fractures of 
the spine, hip, pelvis, femur, leg, ankle, 
upper arm, forearm and hand 
Broad algorithm: fall-related fracture 
without evidence of associated code for 
non-fall causes. 
Narrow algorithm: fall-related fracture 
with associated code for falls. 
≥1 outpatient claim with ICD-9-CM 
diagnosis code for hypoglycemia 
(hypoglycemic events allowed to 
occur at any time during evaluation 
period, including after fracture) 
Multiple logistic regression 
 
Confounders: patient demographics, 
baseline co-morbid conditions, baseline 
medications, CCI, medical encounters 
for diabetes, total baseline medical 
expenditures, number of medical codes 
aOR for fall-related 
fractures 1.70 (1.58, 
1.83). 
Findings were similar for 
both the broad and 
narrow algorithm. 
Kacharoo 2015 
(Kachroo et al., 
2015) 
Admin claim data for fall-related events 
(ICD-9-CM codes for fractures and head 
injury, with fall being the external cause  
based on ICD-9-CM E-codes E880-E888 
recorded within +/-2 days of each other 
in any order. 
 
Admin claim data 
 
ICD-9-CM codes 250.8, 251.0, 251.1 
and 251.2 
Logistic regression analysis 
 
Patients matched on age and gender; 
statistical adjustment on CCI  
Risk of fall-related 
events aOR 1.95 (1.70, 
2.2) 
Fracture – aOR 2.16 
(1.74 -2.67) 
 
Khunti 2015 
(Khunti et al., 
Cardiovascular event defined as a 
composite of MI, stroke or 
Data on hypoglycemic episodes were 
obtained from HES via ICD-10 codes 
Mutivariate Cox regression models 
Covariates: age, sex, smoking status, 
All-cause mortality for 
T2DM: HR 1.94 (1.52, 
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2015) cardiovascular death (cause of death 
obtained through linkage to Office for 
National Statistics).   
9E16.0, E16.2) geographical region, history of 
cardiovascular events before index date, 
use of oral antidiabetic medications, 
Charlson comorbidity index, BMI, HbA1c 
 
2.47)  and 2.39 (2.13, 
2.67) for those with and 
without a history of CVD 
Cardiovascular events 
for T2DM: HR 1.70 (1.09, 
2.64) and 1.50 (1.19, 
1.88) for those with and 
without a history of CVD 
Majumdar 
2013 
(Majumdar et 
al., 2013) 
Primary outcome: all-cause mortality 
Secondary end points included all-cause 
hospitalisations and hypoglycemia-
associated hospitalisations. 
Mortality and dates of hospitalisation 
determined by linkage to provincial 
health ministry databases. 
Defined severe hypoglycemia by the 
presence of any inpatient discharge 
diagnosis of hypoglycemia (ICD-10 
code E15 or E16) 
Multivariable Cox proportional hazard 
methods 
Adjusted for age, sex, socioeconomic 
status (based on individual health 
insurance premium level and median 
neighbourhood income), index eGFR, 
prevalent hypoglycemia, co-morbidities, 
use of diabetes medications 
Mortality associated 
with any hospitalisation 
with hypoglycemia in 
patients with diabetes: 
aHR 2.46 (2.17, 2.80) 
 
McCoy 2012 
(McCoy et al., 
2012) 
Ascertainment of mortality from medical 
records and social security death index 
Investigator asked patients about 
hypoglycemic events 
-mild hypoglycemia: symptoms 
consistent with hypoglycemia not 
requiring any assistance 
-severe hypoglycemia: similar 
symptoms requiring external 
assistance 
Logistic regression 
 
Confounders: age, gender, type of 
diabetes and duration, CCI, HbA1c 
OR 3.38 (1.55, 7.39) 
 
Association between 
severe hypoglycemia 
and 5 year mortality 
Mellbin 2013 
(Origin Trial 
Investigators et 
al., 2013) 
Composite of cardiovascular death (any 
death for which no non-cardiovascular 
cause could be identified), non-fatal MI 
(based on clinical presentation, elevated 
cardiac markers, and /or new 
electrocardiographic changes), or stroke 
(based on clinical presentation and 
imaging) 
-Mortality 
Participants recorded hypoglycemic 
events with glucose meters and 
diaries.  
Investigators asked about 
hypoglycemia at each study visit. 
Non-severe hypoglycemia: relevant 
symptoms confirmed by glucose 
reading <3mmol/L. 
-severe hypoglycemia: symptomatic 
Propensity score matching, as well as 
Cox regression models addressing 
potential confounders: age, gender, 
ethnicity, education, prior cardiovascular 
events, hypertension, depression, 
current smoking, alcohol intake, 
albumin/creatinine ratio >30 mg/g, 
diabetes and cardiovascular drugs, BMI, 
waist-hip ratio, HbA1c, fasting plasma 
In those with severe 
hypoglycemia HR 1.58 
(1.24, 2.02) for 
composite event. 
 
HR 1.71 (1.27, 2.30) for 
cardiovascular death. 
 
HR 1.74 (1.39, 2.19) for 
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Blinded independent adjudication of 
outcomes 
hypoglycemia requiring  assistance of 
another person with (i) prompt 
recovery after oral carbohydrate 
and/or (ii) documented plasma 
glucose level <2mmol/L 
glucose, lipids, serum creatinine, mini-
mental status, prior diabetes mellitus 
total mortality. 
 
 
Rajpathak 2015 
(Rajpathak et 
al., 2015) 
Hip fracture defined as an ICD-9 code 
820.xx recorded at any clinical 
encounter. 
ICD-9 codes based on validated 
algorithm 
Multivariable logistic regression  based 
on propensity score as well as 
adjustment for confounders:: age, sex, 
Medicare cover, region, coronary heart 
disease, stroke, osteoporosis, dementia, 
CKD 
aOR 2.42 (1.35, 4.34) for 
hip fractures in those 
with documented 
hypoglycemia 
Rathmann 2013 
(Rathmann et 
al., 2013) 
Macrovascular complications were 
determined based on primary care 
diagnoses (ICD-10 codes) for coronary 
heart disease (I20, I24 and I25), MI (I21, 
I22, I23 and I25.2), stroke (I63, I64, G45) 
and peripheral vascular disease (E10.5, 
E11.5, E14.5 and I73.9) 
ICD-10 codings (E16.0, E16.1, E16.2) 
Frequency of patients with >1 
hypoglycemic event assessed 30, 90, 
183, 365 and 730 days after index 
date 
Adjusted for age, sex, type of practise 
(diabetologist), practise region, health 
insurance status (private), antidiabetic 
co-medication, episodes of 
hypoglycemia, microvascular 
complications, hypertension, 
hyperlipidaemia, antihypertensive, lipid-
lowering and antithrombotic drugs and 
Charlson co-morbidity index 
HR 1.6 (1.1, 2.2) for 
incident macrovascular 
complications 
Signorovitch 
2013 
(Signorovitch et 
al., 2013) 
Inpatient and emergency department 
claims based on ICD9-CM codes, 
grouped into three codes: accidental 
falls, motor vehicle accidents and other 
accidents 
ICD-9-CM codes for hypoglycemia at 
any place of service 
Multivariable Cox-proportional hazard 
models adjusted for age, gender, 
demographics, co-morbidities of 
diabetes, accident risk factors, CCI, 
inpatient admissions, use of oral 
hypoglycemics. 
Hypoglycemia associated 
with accidental falls aHR 
1.36 (1.13, 1.65) 
For age >65: aHR 1.52 
(1.18, 195) 
Zhao 2012 
(Zhao et al., 
2012) 
ICD-9-CM codes. 
Macrovascular: MI, stroke, congestive 
heart failure, peripheral vascular 
disease. 
Microvascular: renal, ophthalmic or 
neurologic manifestations with diabetes. 
ICD-9-CM codes Propensity score matching (greedy 5 to 
1 method) for noncomparable baseline 
characteristics  
Cox proportional hazard regression 
models controlling for covariates, 
including  baseline demographic and 
illness characteristics, vital signs, prior 
HR 2.00 (1.63-2.44) for 
cardiovascular events, 
HR 1.76 (1.46, 2.11) for 
microvascular 
complications 
HR 1.29 (0.94, 1.77) for 
mortality. 
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medication, and index drug  
Zhao 2015 
(Zhao et al., 
2015) 
Fall-related events (fractures, head 
injuries) defined using ICD-9-CM 
codes between 800.x-995.x, with a fall 
being the external cause (based on ICD-
9-CM E-codes E880- E888 within two-
day window). 
ICD-9-CM codes McNemar tests, Generalised estimating 
equation (GEE) 
Matching on age, gender, ethnicity and 
medical service 
Adjustments for social demographic and 
illness characteristics, vital signs and 
medication use 
aOR 2.70 (1.64, 4.47) for 
fall-related events in the 
hypoglycemia group 
Zoungas 2010 
(Zoungas et al., 
2010) 
First major macrovascular event=death 
from cardiovascular cause, non-fatal MI, 
non-fatal stroke 
First major microvascular event=new or 
worsening nephropathy or retinopathy 
Secondary outcomes=death from any 
cause and death from a cardiovascular 
event 
 Independent adjudication by blinded 
committee 
 
Blood glucose level <2.8 mmol/L or 
typical symptoms/signs without 
other apparent cause.  Those with 
transient neurological dysfunction 
who required help from 3
rd
 party 
were considered to have severe 
hypoglycemia.  Minor hypoglycemia 
if transient dysfunction of CNS and 
able to treat themselves. 
Cox proportional-hazard models 
adjusted for covariates. 
Baseline: sex, duration of diabetes, 
treatment allocation, history of 
macrovascular or microvascular disease, 
ever smoker.  
Time dependent covariates during 
follow-up: age, HbA1c, body mass index, 
creatinine, urine albumin to creatinine 
ratio, systolic blood pressure, diabetes 
and blood pressure drugs. 
HR 2.88 (2.01, 4.12) 
major macrovascular 
events, HR 1.81 (1.19,  
2.74) major 
microvascular events, HR 
2.68 (1.72, 4.19) death 
from cardiovascular 
cause, HR 2.69 (1.97, 
3.67) death from any 
cause 
 
 
OR= Odds ratio, HR=Hazard ratio, 95% CI= 95% Confidence Interval, T2DM=Type 2 diabetes mellitus, HbA1C=glycated haemoglobin, CKD=chronic kidney disease, DPP-
4=dipetidyl-peptidase-4, SU=Sulfonylureas, MI=myocardial infarction, AF=atrial fibrillation, CVD= cardiovascular disease, HES=Hospital Episode Statistic, CPRD= Clinical 
Practice Research Datalink database, TUG=Timed Up and Go Test, GDS-15=Geriatric Depression Scale, CCI= Charlson comorbidity index, IFG=impaired fasting glucose, IGT= 
impaired glucose tolerance 
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Figure 1. Meta-analysis of association between hypoglycemia and vascular events 
 
 
Figure 2. Meta-analysis of association between hypoglycemia and falls and fractures 
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Figure 3. Meta-analysis of association between hypoglycemia and mortality 
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